Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paolo F Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, MD, Kirit M. Ardeshna, Mehdi Hamadani, MD, Brian T. Hess, MD, Brad S. Kahl, MD, John A. Radford, MD FMedSci, Melhem Solh, MD, Anastasios Stathis, MD, Pier Luigi Zinzani, MD, Jay Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella, MD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-137524

Published: 2020

Journal Articles

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Filippo Spriano, Gaetanina Golino, PhD, Lorenzo Scalise, Emanuele Zucca, MD, Anastasios Stathis, MD, Patrick H Van Berkel, PhD, Francesca Zammarchi, PhD, Francesco Bertoni, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-134664

Published: 2020

Journal Articles

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Panayiotis Panayiotidis, MD, Gayane Tumyan, Catherine Thieblemont, Vadim V Ptushkin, Ana Marin Niebla, Ramon Garcia-Sanz, Andrey Zaritskey, Steven Le Gouill, MD PhD, Christian Buske, MD, Marlies Van Hoef, Thomas Perretti, Monique S Tomiczek, Anastasios Stathis, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137087

Published: 2020

Journal Articles

Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142000

Published: 2020

Journal Articles

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Alberto J Arribas, Sara Napoli, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Alessandra Di Veroli, Chiara Tarantelli, PhD, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, PhD, Andrea Rinaldi, Anastasios Stathis, MD, Georg Stuessi, MD, Valter Gattei, MD, Gabriele Cruciani, Emanuele Zucca, MD, Davide Rossi, MD PhD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2569.

https://doi.org/10.1182/blood-2019-124299

Published: 2019

Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford

Blood (2019) 134 (Supplement_1): 757.

https://doi.org/10.1182/blood-2019-128401

Published: 2019

Journal Articles

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Filippo Spriano, Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Gaetanina Golino, Luciano Cascione, PhD, Emanuele Zucca, Anastasios Stathis, MD, Francis J. Giles, MD FRCPI, FRCPath, Francesco Bertoni, MD

Blood (2018) 132 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2018-99-114900

Published: 2018

Journal Articles

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Andrew D. Zelenetz, MD PhD, Jacob D. Soumerai, MD, Deepa Jagadeesh, MD MPH, Nishitha Reddy, MD, Anastasios Stathis, MD, Adam S. Asch, MD, Huda S. Salman, MD, Vaishalee P. Kenkre, MD, Haresh Jhangiani, MD MBA, Alexia Iasonos, PhD, Patel Krish, MD, Richard G Ghalie, MD MBA, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2018-99-115670

Published: 2018

Journal Articles

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Elaine Y Chung, PhD, Filippo Spriano, Ivo Kwee, PhD, Sara Napoli, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Andrea Cavalli, Alberto Arribas, PhD, Andrea Rinaldi, Davide Rossi, MD PhD, Emanuele Zucca, MD, Anastasios Stathis, MD, Katti Jessen, PhD, Brian J Lannutti, PhD, Jeffrey Toretsky, MD, Francesco Bertoni, MD

Blood (2017) 130 (Supplement 1): 2810.

https://doi.org/10.1182/blood.V130.Suppl_1.2810.2810

Published: 2017

Journal Articles

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 307.

https://doi.org/10.1182/blood.V130.Suppl_1.307.307

Published: 2017

Journal Articles

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Blood (2017) 130 (Supplement 1): 1506.

https://doi.org/10.1182/blood.V130.Suppl_1.1506.1506

Published: 2017

Journal Articles

The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas

Chiara Tarantelli, Eugenio Gaudio, Ivo Kwee, Luciano Cascione, Elena Bernasconi, Petra Hillmann, Anastasios Stathis, MD, Georg Stussi, MD, Doriano Fabbro, Andreas Wicki, Emanuele Zucca, Vladimir Cmiljanovic, Francesco Bertoni

Blood (2015) 126 (23): 4005.

https://doi.org/10.1182/blood.V126.23.4005.4005

Published: 2015

Journal Articles

The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma

Elena Bernasconi, B.Sc., Chiara Tarantelli, Eugenio Gaudio, PhD, Ivo Kwee, Andrea Rinaldi, Luciano Cascione, Anastasios Stathis, MD, Maria Eugenia Riveiro, MD PhD, Emanuele Zucca, MD, Francesco Bertoni

Blood (2014) 124 (21): 3113.

https://doi.org/10.1182/blood.V124.21.3113.3113

Published: 2014

Journal Articles

BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma

Luciano Cascione, Eugenio Gaudio, PhD, Elena Bernasconi, B.Sc., Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, B.Sc., Riccardo Bomben, Valter Gattei, Ivo Kwee, PhD, Anastasios Stathis, MD, Maria Eugenia Riveiro, MD PhD, Emanuele Zucca, MD, Francesco Bertoni

Blood (2014) 124 (21): 4495.

https://doi.org/10.1182/blood.V124.21.4495.4495

Published: 2014

Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

Catherine Thieblemont, MD PhD, Anastasios Stathis, MD, Giorgio Inghirami, MD, Lionel Karlin, Franck Morschhauser, MD PhD, Mary Gleeson, FRCPath, Florence Broussais, MD, Sandy Amorim, MD, Gilles Salles, MDPhD, Thierry Facon, MD, David Cunningham, FMedSci, Norbert Vey, MD PhD, Fabrice Bourdel, MSc, Patrice Herait, MD, Emanuele Zucca, MD

Blood (2014) 124 (21): 4417.

https://doi.org/10.1182/blood.V124.21.4417.4417

Published: 2014

Journal Articles

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Anastasios Stathis, MD, Arnold S. Freedman, MD, Ian W. Flinn, MD, Kami J. Maddocks, MD, Steven Weitman, MDPhD, Jesus G. Berdeja, MD, Alex V. Mejia, MD, Emanuele Zucca, MD, Rebecca Green, Angela Romanelli, PhD, Sybil H Zildjian, MPH, Rodrigo Ruiz-Soto, MD MSc, Lia Palomba, MD

Blood (2014) 124 (21): 1760.

https://doi.org/10.1182/blood.V124.21.1760.1760

Published: 2014

Journal Articles

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren’s Disease and May Not Benefit from Local Therapy

Amie E Jackson, MD, Michael Mian, Christina H. Kalpadakis, MD, Gerassimos A Pangalis, MD, Anastasios Stathis, MD, Elena Porro, MSc, Ellen D McPhail, MD, Thomas M Habermann, MD, Kay M. Ristow, Franco Cavalli, MD, Grzegorz S. Nowakowski, MD, Emanuele Zucca, MD

Blood (2014) 124 (21): 1637.

https://doi.org/10.1182/blood.V124.21.1637.1637

Published: 2014

Journal Articles

The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

Chiara Tarantelli, Eugenio Gaudio, PhD, Ivo Kwee, PhD, Andrea Rinaldi, Matteo Stifanelli, Elena Bernasconi, B.Sc., Chiara Barassi, Petra Hillmann, Anastasios Stathis, MD, Laura Carrassa, Massimo Broggini, Georg Stussi, MD, Doriano Fabbro, Paul Hebeisen, Frances Betts, Andreas Wicki, Emanuele Zucca, MD, Vladimir Cmiljanovic, Francesco Bertoni

Blood (2014) 124 (21): 1782.

https://doi.org/10.1182/blood.V124.21.1782.1782

Published: 2014

Journal Articles

Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations

Eugenio Gaudio, PhD, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Michela Boi, PhD, Elena Bernasconi, B.Sc., Monica Testoni, B.Sc., Anastasios Stathis, MD, Patrice Herait, MD, Kay Noel, PhD, Giorgio Inghirami, Emanuele Zucca, MD, Francesco Bertoni, MD

Blood (2013) 122 (21): 3070.

https://doi.org/10.1182/blood.V122.21.3070.3070

Published: 2013

Journal Articles

Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells

Swaroop Vakkalanka, PhD, Srikant Viswanadha, Ph.D., Eugenio Gaudio, PhD, Emanuele Zucca, MD, Francesco Bertoni, MD, Elena Bernasconi, B.Sc., Davide Rossi, MD, Ph.D., Anastasios Stathis, MD

Blood (2013) 122 (21): 4411.

https://doi.org/10.1182/blood.V122.21.4411.4411

Published: 2013

NARROW

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas

The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma

BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren’s Disease and May Not Benefit from Local Therapy

The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations

Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only